Emvena launches with Penn-BioNTech seed funding to treat preeclampsia at its source
What's the deal? EmvenaDealroom has a profile for this one. Try Dealroom → Therapeutics has emerged from stealth with seed funding from the Penn-BioNTech Innovative Therapeutics Seed Fund (PxB Fund) to develop a treatment for preeclampsia, a pregnancy complication that carries serious risks to maternal and fetal health. The Houston biotech was co-founded by Rice University faculty member Kelsey Swingle, building on research from her doctoral work at the University of Pennsylvania. The amount was not disclosed.
What's the endgame? Preeclampsia affects 2–8% of pregnancies worldwide, and care today centres on monitoring and managing symptoms — with delivery of the baby one of the only treatments. Emvena is instead targeting the biological processes in the placenta that drive the condition, aiming for a disease-modifying therapy.
Its platform uses lipid nanoparticles — the delivery technology behind mRNA medicines — to direct therapeutic payloads to the placenta. In mouse studies, the approach delivered mRNA encoding vascular endothelial growth factor, helping reverse high blood pressure and improve placental and fetal health.
Who's involved? Young T. Kwon is co-founder, chief executive officer, and executive chair. Other co-founders include Michael Mitchell, a professor of bioengineering at the University of Pennsylvania, alongside Hannah Safford and Dr. Allison August. Anna Turetsky, general partner at the PxB Fund, joins the board.
"By developing a targeted drug delivery approach focused on the placenta, we aim to translate this technology into a therapeutic strategy that could improve outcomes for mothers and their babies," Kwon said.
Why now? Swingle is an assistant professor of bioengineering and a member of the Rice Biotech Launch Pad, an accelerator focused on turning university discoveries into treatments. "Translating a scientific discovery from the lab into a clinically available therapy requires more than strong science," she said. "It also requires building the right team that understands how to advance innovation toward patients."
What could go wrong? The program remains preclinical. The company plans to advance toward clinical development, but further research is needed to establish safety and efficacy in humans.
The signal: Emvena is part of a broader push to tackle preeclampsia's underlying biology rather than its symptoms — a shift that in August drew a commitment of up to $35 million from the Gates Foundation to ProFound Therapeutics. The round is also the first company financing from the new $50 million PxB Fund, marking an early-stage bet on an area of substantial unmet need.
Read more: pr.sandyjournal.com
Image credit: Generated with Gemini
